Asymmetric dimethylarginine-A potential cardiac biomarker in horses.

This research study investigates the potential of Asymmetric dimethylarginine (ADMA) as a cardiac disease biomarker in horses, utilizing established ELISA detection methods. Highlighting ADMA’s increased presence in horses with heart disease, it suggests that the substance along with the l-Arginine/ADMA ratio could assist in identifying cardiac issues in horses.

Objective and Methods

• The prime objective of this study was to evaluate whether measuring serum ADMA and symmetric dimethylarginine (SDMA) levels via ELISA (Enzyme-Linked Immunosorbent Assay) could help detect cardiac disease in horses.
• A total of 101 horses were included in the research. This cohort consisted of 78 healthy horses and 23 horses with confirmed structural heart disease, including some with arrhythmias.
• The horses were subjected to a physical examination, electrocardiography, echocardiography, and venous blood sampling. They were categorized based on the severity of their cardiac disease, ranging from stage 0 to stage II.
• The serum concentrations of ADMA and SDMA were authenticated through ELISA. This was cross-verified using a liquid chromatograph triple quadrupole mass spectrometer, a highly accurate tool for detecting chemicals in a sample.

Results and Conclusion

• The research found that the normal ADMA concentration in healthy horses was between 1.7 and 3.8 µmol/L, while the normal SDMA concentration ranged from 0.3 to 0.8 µmol/L.
• It was found that serum ADMA concentration was noticeably higher in horses suffering from heart disease compared to healthy horses. Maximum levels were noted in horses with stage II heart disease.
• The l-Arginine/ADMA ratio was considerably higher in healthy horses than in those afflicted with cardiac disease. This suggests that a lower ratio might be indicative of heart disease in horses.
• The study concludes by establishing reference values for serum ADMA and SDMA using ELISA methods in horses. It also confirms the correlation between heart disease and an increased level of ADMA and a decreased l-Arginine/ADMA ratio.